Rasmus Wied Pedersen

Untap the Startup Potential- A comparative 59 slide review of the Danish life science Startup Ecosystem addresses How the Danish life science startup ecosystem performs? and beyond at https://lnkd.in/gA8356-K. Highlights: 1) Compared to the other hubs, Denmark performs fairly well in terms of available capital per startup with 7.3 million USD per company. This is a relevant size for funding early-stage companies 2) The ecosystem around IPOs is not as mature in Denmark, which limits the long-term funding potential of startups. This could be developed actively with more specialized lawyers, investment bankers, and corporate developers 3) Although Denmark scores relatively well in terms of talent attraction, a criticism is that Denmark does not attract the “right people” (i.e. CEOs, CTOs, and CMOs who have “done it before”). Incentives could be improved to target these talents more 4) The BioInnovation Institute https://lnkd.in/dJK9VGWq

3

I love the idea behind Mark Davison's podcast "The Big Experiment": Stories of scientists who have made the leap from researcher to entrepreneur. So it was a pleasure to be a guest on the latest episode and tell the story behind Green Elephant Biotech. We talked about the status quo and future of sustainability in life science labs and our cell culture technology. Enjoy the episode (link in comments)! #podcast #lifescience #biotech #CGT #sustainability

30

4 Comments

The European Biosolutions Coalition was thrilled to have our colleague, Marit Hvithamar Rystrøm, participate in the recent UK-Nordic-Baltic Biology Workshop in Stockholm. 🇸🇪 This multi-day event proved once again the importance of bringing engineering biology and biosolutions to the forefront of European agenda, a testament to the growing importance throughout the European and also regional dimensions. 🌍 It's incredibly encouraging to witness the evolution of this agenda, now extending to regional workshops and discussions such as this dialogue. These gatherings are not only the place for fruitful discussion on how we pave the way towards a green future, but also serve as vital platforms for collaboration, hearing new perspectives and supporting insightful contributions to addressing the pivotal role of engineering biology and biosolutions in addressing global sustainability challenges. 🔍 Through engaging discussions, workshops and networking sessions, we explored cutting-edge developments and discussed challenges and opportunities going forward. Among the notable speakers for the panel discussions were representatives from, among others, BioInnovation Institute, DTU Biosustain and Vinnova. A big thank you to all organizers from Science & Innovation Network at the British Embassy, speakers and participants who made this event a resounding success. We look forward to continuing these collaborations and pushing boundaries of what we can achieve with biosolutions. 🙌 #EUBioCoalition #Biosolutions #GreenTeansition #Sustainability #Resilience #Competitiveness

28

2 Comments

Danish biotech startup raises €4.9M to scale sustainable alternative to petrochemicals Søborg-based biotech startup CELLUGY® has secured €4.9M in seed funding from leading investors including ICIG Ventures, Unconventional Ventures, Joyance Partners, PreSeed Ventures DeepTech, The Footprint Firm, and Export and Investment Fund of Denmark (EIFO). Cellugy specializes in developing natural, biofabricated cellulose-based solutions to replace fossil-based materials in various industries. The funding will be used to scale up production of their EcoFLEXY dry cellulose product, which is currently in the pilot phase, to industrial volumes. This will enable Cellugy to meet increasing customer demand and explore new application areas for their sustainable alternative to petrochemical ingredients. https://lnkd.in/driSR9ax #nordicmade #denmark #funding #startups #biotech #deeptech #trending

64

Are you a PhD or Master's student working on cell culture or cultured meat?  We have the perfect solution for you! 🎓 Quest cells are not just fast growing and high-performing, they also come with comprehensive user guides that walk you through every step of the process - from seeding and expansion to differentiation 🤝 Did you know that the quality of the cells you use directly determines the success of your experiments? Factors such as how cells have been isolated and expanded can significantly affect cell growth, adhesion, and differentiation downstream 🤔 At Quest we offer high-quality, sterility tested cell lines, that have been isolated using our proprietary in-house technique, resulting in significantly faster-growing cells than standard methods! 📈 We provide cells from multiple tissues (fat, muscle, bone marrow) and species (cow, pig, water buffalo) 🐮🐃 🐷 In addition to customer support all our cells come with expansion data, differentiation data and identity markers 🔬 One more thing! All of our cells are license-free for R&D purposes! 💸 With our cells, you're never alone in the lab - consider us your partners, providing support every step of the way 💪 Contact us today at info@questmeat.com to enhance your research 📩 #Researcher #AcademicLife #STEM #Students #phdlife #phdresearcher #phdstudent #culturedmeat #CultivatedMeat #celllines #innovation #FutureOfFood 

10

With this hackerton we give further insights into our hyperautomtion technology and the increasing power of our neuro-symbolic-xyna.ai as the engine of xyna.bio.

3

Exciting News: Alligator Bioscience AB published on a novel bispecific antibody format. The RUBY bispecific antibody (bsAb) format features a 2 + 2 geometry, linking two Fab fragments to an IgG, with mutations for optimal chain pairing. ✅ This design facilitates the rapid creation of bsAbs meeting key development criteria. ✅ They demonstrate tailored Fc gamma receptor binding, while retaining FcRn interaction for pharmacokinetics like monoclonal antibodies (mAbs). ✅ Octet®️ BLI was used for kinetic measurements to confirm their functionality and demonstrate their antitumor potential. Read the article here: https://ow.ly/rXvy50RHXaA #OctetBLI #BLI #Biotechnology #Immunotherapy #FcReceptors #BispecificAntibodies #Pharmacokinetics #Innovation #ScienceNews #ClinicalResearch #FcGammaReceptors #ClinicalPotential #cancer

39

3 Comments

Results of a recent Nordic EMBL Partnership for Molecular Medicine collaboration project propose that increased fiber intake in humans has the potential to shape the gut bacteria into a configuration that improves mucus function. The findings of the study were just published in Nature Communications. In this study, research fellow Bjoern O. Schroeder, PhD and his group at The Laboratory for Molecular Infection Medicine Sweden, MIMS show that increased fibre intake in humans enriches for the beneficial gut bacterium Blautia. The researchers used various methods, including human-to-mouse microbiota transplantation and metabolomics, produced and analysed in collaboration with the FIMM Metabolomics Unit headed by Anni Nieminen. #research #health #microbiomics #metabolomics #nordiccollaboration

7

Do you have variable glucose levels during the day? I know it can be a pain for those that have predisposition for putting on weight or developing diabetes. Fostering innovation in healthcare startups is a tough thing, but there is hope. And hope this time comes from Sigrid Therapeutics with their interesting product named SiPore®, a company I discovered today through a Genetic Engineering & Biotechnology News magazine. Sigrid Tx has spent almost a decade researching, engineering, conducting clinical studies, and scaling up production of silica. They have raised ~ $20m, which is a fair amount of funding for such a product that needs extended clinical trials. An interesting fact is that in the US, SiPore - the main ingredient of Sigrid’s products—is considered a supplement, while in the EU, SiPore is considered a medical device. Tell me about clarity of what is considered what in various jurisdictions around the world, making it tough for radical biotech startups to expand easily with a more standardized healthcare regulatory framework. Personally, I haven't seen something similar before, a medtech product built like this. I, only, remember some years ago, is it 5 or 6 - I am not sure, when I took part in a business hackathon at Copenhagen Business School. One of the teams had this fantastic idea of creating a futuristic small adhesive device which could be mounted at the side of your arm, for the tracking of your blood's sugar levels. That device would be so smart that it would release by itself insulin for those having diabetes. But here, Sigrid Tx has brought something else in the market. Sigrid has engineered micro-sized silica particles that have various levels of porosity that are ingested orally. Then inside the gut, those silica good particles separate in a smart way the digestive enzymes from undigested food that cause metabolic issues, propping up overall health. And as the silica particles are not absorbed, when nature calls you the next (hopefully) day, they will be sent down the drain. In my effort to find innovative companies, that follow novel approaches in curing or treating human health conditions, I have found quite a bunch intriguing R&D-led biotechs out there. More to come... P.S In the image we see Sana Alajmovic and Tore Bengtsson, cofounders of Sigrid Therapeutics.

15

2 Comments

In a breakthrough, a novel mRNA vaccine shows promise against brain cancer -- tested in dogs and humans (link in the comments). This is just to the point of my previous post about the promise of mRNA-based treatments and our new portfolio company, HelixNano who also builds an mRNA discovery platform. In the present study, conducted at the University of Florida the mRNA cancer vaccine incorporates patient-specific tumor cells and a novel cluster delivery system using lipid nanoparticles. Interestingly, the vaccine was tested not only in preclinical mouse models, but in pet dogs with brain cancer, and an initial human clinical trial with four patients. This vaccine targets tumors by turning them from 'cold' (less immune-responsive) to 'hot' (more immune-responsive) and it is reported to trigger a rapid immune response within days. Early trials are promising. The research is moving into expanded Phase I clinical trials with both adult and pediatric patients to further assess safety and efficacy. I find the news especially interesting as it touches my other investment focus -- pet tech and research related to pets. On a side note, I am in Japan this and next week, drop me a line if you are a startup in aging research or in a pet technology market. #cancervaccines #mRNA #research Image credit: Neuroscience News

46

3 Comments

https://lnkd.in/e99SDNPb Blink and you might miss a new development in #Neuromuscular. Takeda has a label expansion on their #SubQIg product. It is now approved in #CIDP. Are all Ig products the same? Perhaps not when talking about the SubQ experience and clearly not when talking about #stabilizer and #osmolarity with the IV products. Where do Ig products fit with FcRn products potentially coming? It remains an open question. My guess: it is hard to knock an established market leader off. Ig products work for many patients with #CIDP and continue to have efficacy data across the spectrum of inflammatory neuropathic disorders.

3

New long-term data for Novo Nordisk’s #Wegovy (semaglutide), published this week in Nature https://lnkd.in/drkXyH5x, has added further weight to the anti-obesity drug’s “miracle” benefits. These new findings from the large-scale SELECT trial show that patients receiving the drug sustained weight loss for up to four years. Further analyses of semaglutide data, presented at the European Society of Cardiology #HeartFailure2024 congress in Lisbon this week, also showed that heart failure-associated biomarkers decreased in patients receiving Wegovy, regardless of the extent of weight loss, suggesting direct cardiac benefits of the drug -- independent of any weight-reduction benefits. These findings add to the wave of data published for the GLP-1 RA, which has been shown to result in ~17% weight loss in people with obesity, while also reducing the risk of obesity-related comorbidities including major adverse cardiac events, heart failure, and osteoarthritis. Further benefits have also been shown for semaglutide in Type 2 Diabetes (under the brand name #Ozempic) and related comorbidities, including a 24% risk reduction in kidney disease-related events in people with T2D and chronic kidney disease. So what does this mean? This new data will grow confidence in the longer-term broad cardio-renal-metabolic benefits of semaglutide with Novo Nordisk seeking label expansions for semaglutide in obesity and T2D-related comorbidities. The impact could be even wider-reaching; with cardiac benefit data potentially supporting increased access to semaglutide in regions, including the U.S., that have historically not reimbursed anti-obesity medications. In light of this new data and its potential implications, we can expect to see Novo Nordisk continuing to drive home the message that obesity is a serious chronic disease with a significant unmet need, associated with many complications. The marketing machine behind Wegovy and Ozempic has successfully driven consumers into a frenzy to take advantage of the broad weight-loss and cardiovascular benefits of these drugs, with conventional direct-to-consumer advertising (in the U.S.) also bolstered by the Hollywood hype and social media noise behind the GLP-1 RA class. However, to date, Novo Nordisk seems to remain a victim of its own successful marketing campaigns, as it struggles to meet consumer demand, with it recently investing heavily in manufacturing plants to scale up production. And while the media hype has worked in semaglutide’s favour to date, there is increasing noise around potential side effects, with “Ozempic face” widely reported, leaving a question mark over how long Novo Nordisk may be able to control the positive narrative in the mainstream media before the tide starts to turn. Analysis authored by Solici Senior Consultant Jonathan Barrow and Consultant Alexandra Holden

32

We've had an action packed schedule at this week's Why Summits Biotech/Pharma PPM conference. Got the chance to chat with a number of very talented PMs and to learn from the best (Stephen Smith, Joe Stalder, Magnus Ytterstad, Feng Gu, SHOBA GOPALAN, and so many more). Lots of questions about AI and how people are using it to support activities in the PMO and in team building. My personal nerdvana use case for this is applying AI to find the right people with the right experience, to improve the odds of success for a drug discovery project. You can imagine pulling together skills & experience (LinkedIn), publication history (ORCID & PubMed), project team history (Pipeline), along with emotional intelligence information to construct a team that's the right combination of leaders and learners. Or how can I take lessons learned from multiple projects over time, and use that to proactively push that information to the right people, at the right time on the right projects. Anyway, lots of great ideas floating around this conference. Looking forward to Day 2. #biotech #pharmaceutical #PPM #projectmanagement

20

2 Comments

Very interesting article from Elliot Hershberg. Pharma like other regulated domains are very conservative. If you want to foster innovation, regulation must adapt itself. As usual, I don't say "no or less regulation", but smart regulation ;-) "In the future that Urnov dreams of—and that the FDA is increasingly sympathetic towards—this all could change. Imagine if the draft guidance for platform approvals is passed into law. A company like Intellia could gain approval for platforms rather than products. The fundamental technology underlying NTLA-2001 and NTLA-2002 could be approved as a platform for curing genetic diseases of the liver, dramatically reducing the time and development costs associated with curing any one disease." The same is true if you want to drop down the manufacturing costs of biologics....Microbes are a tangible alternative.... Abolis Biotechnologies

5

1 Comment

Are molecular glues the key to undruggable targets?   In case you missed it, Dr Benedict CS Cross spoke with Labiotech.eu about the growing interest in the field of molecular glues and the potential for this new modality to open up immense new possibilities in degrader drug development. Read the full article here: https://rb.gy/pnzjdu   #MolecularGlues #DrugDiscovery #DrugDevelopment

25

1 Comment

Our platform includes some of the smallest Cas proteins known to work in human cells (half the size of Cas9!) — and today we’re proud to take a major step toward enabling other scientists to use them as well. Together with our founder Lei (Stanley) Qi, we are launching the first dCasMINI Guide Design Tool, to make designing guide RNA for dCasMINI as easy as it is for the first-generation Cas9 or Cas12a. The tool, which is freely accessible at https://lnkd.in/gz4jbvJ8, allows researchers to generate optimal gRNA sequences to activate or suppress more than 99% of human genes with just a single click. It also provides a comprehensive genome-wide assessment of off-target matches. To learn more about how the dCasMINI Guide Design Tool works, check out our recent updated preprint: https://lnkd.in/gzYz8bey Our hope is that this tool makes epigenetic modulation studies quicker and easier to perform, and expands access to dCasMINI for researchers across a wide variety of disciplines. #biotechnology #CRISPR #epigenetics #guidedesign

36

1 Comment

To be able to feed a growing population in the world, there is a need of new and industrial solutions for sustainable production of Food and Materials. Good Food Institute Europe is summarizing in this article what we are doing in Northern Europe at Biotech Heights, a recently launched Open Innovation platform. 🌍 Tetra Pak Lund University Vinnova

74

1 Comment

🚀 Exciting News from BioInCRO! 🚀 At BioInCRO, we are passionate about accelerating scientific discovery and innovation. We understand the complexities and challenges that come with bioinformatics projects. That's why we are thrilled to announce a for researchers and organizations! 🌟 Get a FREE Consultation for your bioinformatics project! 🌟 Whether you're tackling genomic data analysis, proteomics, or any area of computational biology, our team of experts is here to provide guidance, optimize your workflows, and help you overcome technical hurdles. Why choose BioInCRO? I. Expert team with deep industry and academic experience II. Cutting-edge computational tools and resources III. Customized solutions tailored to your project's needs This offer is ideal for anyone at the forefront of biological research or in the early stages of a startup looking to make a significant impact in the field. 📅 Book your free consultation today! Spots are limited and will fill up quickly. Let’s collaborate to advance your research and achieve groundbreaking results. Contact us at experts@bioincro.com or visit our website to learn more and book your session. www.bioincro.com #Bioinformatics #Genomics #ComputationalBiology #FreeConsultation #ResearchInnovation #ScienceAndTechnology

1